Leap Therapeutics (LPTX) Competitors $0.29 0.00 (-1.56%) Closing price 04:00 PM EasternExtended Trading$0.29 +0.00 (+0.72%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPTX vs. DTIL, LTRN, BRNS, JSPR, KLRS, TELO, IPSC, ANVS, STTK, and KLTOShould you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Precision BioSciences (DTIL), Lantern Pharma (LTRN), Barinthus Biotherapeutics (BRNS), Jasper Therapeutics (JSPR), Kalaris Therapeutics (KLRS), Telomir Pharmaceuticals (TELO), Century Therapeutics (IPSC), Annovis Bio (ANVS), Shattuck Labs (STTK), and Klotho Neurosciences (KLTO). These companies are all part of the "pharmaceutical products" industry. Leap Therapeutics vs. Its Competitors Precision BioSciences Lantern Pharma Barinthus Biotherapeutics Jasper Therapeutics Kalaris Therapeutics Telomir Pharmaceuticals Century Therapeutics Annovis Bio Shattuck Labs Klotho Neurosciences Precision BioSciences (NASDAQ:DTIL) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Do insiders and institutionals have more ownership in DTIL or LPTX? 38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are owned by institutional investors. 4.0% of Precision BioSciences shares are owned by insiders. Comparatively, 7.5% of Leap Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, DTIL or LPTX? Precision BioSciences has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.21, indicating that its share price is 121% less volatile than the S&P 500. Does the media prefer DTIL or LPTX? In the previous week, Precision BioSciences' average media sentiment score of 1.87 equaled Leap Therapeutics'average media sentiment score. Company Overall Sentiment Precision BioSciences Very Positive Leap Therapeutics Very Positive Is DTIL or LPTX more profitable? Leap Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -6,205.79%. Precision BioSciences' return on equity of -176.47% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Precision BioSciences-6,205.79% -176.47% -69.05% Leap Therapeutics N/A -237.65%-155.38% Which has stronger valuation and earnings, DTIL or LPTX? Precision BioSciences has higher revenue and earnings than Leap Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecision BioSciences$68.70M0.87$7.17M-$8.81-0.57Leap TherapeuticsN/AN/A-$67.56M-$1.58-0.18 Do analysts prefer DTIL or LPTX? Precision BioSciences presently has a consensus price target of $47.00, indicating a potential upside of 830.69%. Leap Therapeutics has a consensus price target of $3.38, indicating a potential upside of 1,064.19%. Given Leap Therapeutics' higher possible upside, analysts plainly believe Leap Therapeutics is more favorable than Precision BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryPrecision BioSciences beats Leap Therapeutics on 8 of the 13 factors compared between the two stocks. Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPTX vs. The Competition Export to ExcelMetricLeap TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.01M$3.10B$5.75B$9.83BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-0.1821.2382.4426.63Price / SalesN/A398.88530.80110.54Price / CashN/A43.5325.7028.92Price / Book2.078.1310.646.56Net Income-$67.56M-$53.35M$3.28B$266.04M7 Day Performance-0.03%0.45%-0.08%-0.58%1 Month Performance-5.26%9.94%10.36%6.24%1 Year Performance-89.86%11.73%49.00%22.21% Leap Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPTXLeap Therapeutics1.6371 of 5 stars$0.29-1.6%$3.38+1,064.2%-89.8%$12.01MN/A-0.1840Positive NewsDTILPrecision BioSciences4.1432 of 5 stars$5.13+3.4%$47.00+816.2%-54.0%$58.46M$1.26M-0.58200Positive NewsLTRNLantern Pharma3.0736 of 5 stars$4.57+1.3%$25.00+447.0%-1.5%$48.71MN/A-2.5720News CoveragePositive NewsBRNSBarinthus Biotherapeutics3.4589 of 5 stars$1.20+1.3%$3.00+151.0%-12.1%$48.05M$14.97M-0.69107Positive NewsShort Interest ↓Gap UpJSPRJasper Therapeutics2.811 of 5 stars$2.96+1.0%$28.75+871.3%-87.3%$47.62MN/A-0.4920KLRSKalaris Therapeutics1.2464 of 5 stars$2.51flat$3.00+19.5%N/A$46.94MN/A0.00110Positive NewsAnalyst ForecastTrading HaltedTELOTelomir Pharmaceuticals3.2119 of 5 stars$1.46+0.7%$15.00+927.4%-77.1%$46.81MN/A-2.701Short Interest ↓Gap DownIPSCCentury Therapeutics2.8324 of 5 stars$0.51-5.5%$3.75+633.6%-72.7%$46.75M$6.59M-1.76170Positive NewsANVSAnnovis Bio2.0374 of 5 stars$2.24-5.5%$18.00+703.6%-72.3%$46.18MN/A-1.103News CoverageAnalyst ForecastSTTKShattuck Labs3.1818 of 5 stars$0.99+3.5%$7.00+604.4%-71.9%$45.99M$5.72M-0.82100News CoverageInsider TradeShort Interest ↑Gap UpKLTOKlotho NeurosciencesN/A$0.75+0.7%N/AN/A$45.96MN/A-1.68N/APositive News Related Companies and Tools Related Companies Precision BioSciences Alternatives Lantern Pharma Alternatives Barinthus Biotherapeutics Alternatives Jasper Therapeutics Alternatives Kalaris Therapeutics Alternatives Telomir Pharmaceuticals Alternatives Century Therapeutics Alternatives Annovis Bio Alternatives Shattuck Labs Alternatives Klotho Neurosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPTX) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThe Orphaned Well Crisis Hidden Across AmericaAcross the U.S., millions of abandoned oil and gas wells are leaking methane into the air — a costly and dange...The Tomorrow Investor | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
